Comparing two forms of Ocrelizumab for MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a new form of the multiple sclerosis drug Ocrelizumab (given as a shot under the skin) works as well as the approved version. If you have relapsing or primary progressive MS, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing or primary progressive MS (RRMS or PPMS).
- Your disability level (EDSS) is between 0 and 6.5.
- You have not taken anti-CD20 treatments (like Ocrevus) in the last 2 years.
- You have never had PML (a rare brain infection).
- You have not had cancer (including blood cancer) in the last 10 years.
- You are generally healthy without serious illnesses requiring steroids or immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.